Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia - PubMed
7 hours ago
- #Thrombocytopenia
- #Anticoagulation
- #Hemostasis
- Thrombocytopenia, traditionally linked to bleeding, can paradoxically increase thrombosis risk.
- Anticoagulation and antiplatelet therapy in thrombocytopenic patients require balancing bleeding and ischemic risks.
- Guidelines suggest full-dose anticoagulation for platelet counts ≥50×10⁹/L, with dose adjustments at 25-50×10⁹/L.
- Antiplatelet therapy, especially dual therapy, needs strict individualization based on risk factors.
- Management strategies vary by condition, such as cancer-associated thrombosis, immune thrombocytopenia, and cirrhosis.